Skip to content

Real-world Insights of People With Human Immunodeficiency Virus (HIV) Infection

RISE: Real World Insights of People Living With HIV Shared Through Electronic Devices

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03400293
Acronym
RISE
Enrollment
1184
Registered
2018-01-17
Start date
2018-01-18
Completion date
2018-07-07
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections

Keywords

Human Immunodeficiency virus, Health Related Quality of Life, Functional Assessment of HIV Infection, Mobile app

Brief summary

This study is designed to identify the burden associated with HIV and its treatment, and assess their health-related quality of life (HRQoL) by measuring key HRQoL domains, including satisfaction with treatment and care, and internalised stigma (ISAT). The study will also explore data for various important subpopulations such as subjects who are virally suppressed; who we anticipate will be the majority of study subjects. The study design is an observational, cross sectional study employing subjects' own mobile phone devices for data entry.

Interventions

OTHERFunctional Assessment of HIV Infection

Functional Assessment of HIV Infection will be used to assess HRQoL of subjects. This will include 47 items.

Patient Satisfaction Questionnaire will be used to assess burden and HRQoL in subjects. This will include 18 items.

OTHERSymptom Distress Module

Symptom Distress Module will be used to assess burden and HRQoL in subjects. This will include 20 items.

Patient Health Questionnaire will be used to assess burden and HRQoL in subjects. This will include 2 items.

OTHERInternalized Stigma of AIDS Tool

Internalized Stigma of AIDS Tool will be used to assess burden and HRQoL in subjects. This will include 10 items.

OTHERMedication adherence visual analogue scale

Medication adherence visual analogue scale will be used to assess burden and HRQoL in subjects. This will include 1 item.

Sponsors

Evidera
CollaboratorINDUSTRY
mProve
CollaboratorUNKNOWN
ViiV Healthcare
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* \>= 21 years old * Language:Read and Understand English / Spanish * Positive diagnosis of HIV infection by a healthcare provider (self-reported) * Possesses a smartphone that has internet access

Exclusion criteria

* Not Applicable

Design outcomes

Primary

MeasureTime frameDescription
Percentage of virally suppressed PLHIV reporting different HRQoL scoresUp to 1 WeekEvaluation of HRQoL will be conducted using scores achieved by Functional Assessment of HIV Infection (FAHI). QoL assessment will include physical well-being, social well-being, emotional well-being, functional and global well-being, and cognitive functioning

Secondary

MeasureTime frameDescription
Percentage of virally suppressed PLHIV reporting different satisfaction with care scoresUp to 1 WeekEvaluation of burden will include stigma, stigma, depression, and work productivity. The descriptive analysis will be assessed using Patient Satisfaction Questionnaire (PSQ)-18, Patient Health Questionnaire (PHQ)-2, and ISAT scores
Percent difference in HRQoL scores among subject subgroupsUp to 1 WeekSubject subgroups are defined in terms of the following socio-demographic, clinical, and biomedical factors: a. Age: older versus. younger (i.e., \< 50 years old and over 50 years old) b. Gender (men / women / transgender) c. Race / ethnicity d. Sexual orientation (straight / gay / bisexual) e. Level of income f. Type of Insurance g. Apple (iPhone operating system) versus Android users h. Treatment regimen (e.g., number of pills per day, frequency of medication, single treatment regimen (STR) versus multiple treatment regimen (MTR) i. Diagnosis time / stage at which diagnosis was received (i.e. prompt vs. late diagnosis, time since diagnosis) j. Absence or presence (and number) of comorbidities k. Severity of symptoms (as assessed by the Symptom Distress Module patient reported outcome (PRO) instrument) l. Achievement of viral suppression.
Percentage of subjects reporting different HRQoL scores and relationship with satisfaction with careUp to 1 WeekStatistical correlation of reported QoL scores (FAHI) and satisfaction with care scores (PHQ-18) will be analyzed.
Percentage of subjects reporting diffferent HRQoL and medication adherenceUp to 1 WeekStatistical correlation between QoL scores (FAHI) and adherence scores (adherence VAS) will be analyzed.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026